$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

$imuc Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000156459014005433 Filed on November 10, 2014

Income Statement

Concept	2014 Q3	2013 Q3
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$960.0K	$1.140M
YoY Change	-15.79%	9.62%
% of Gross Profit
Research & Development	$1.490M	$1.280M
YoY Change	16.41%	-46.22%
% of Gross Profit
Depreciation & Amortization	$12.93K	$14.00K
YoY Change	-7.63%	22.33%
% of Gross Profit
Operating Expenses	$2.440M	$2.420M
YoY Change	0.83%	-29.24%
Operating Profit
YoY Change
Interest Expense	$550.0K	-$1.380M
YoY Change	-139.86%	-149.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.890M	-$3.790M
YoY Change	-50.13%	492.19%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.889M	-$3.793M
YoY Change	-50.2%	494.93%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03	-$0.07
Diluted Earnings Per Share	-$0.03	-$0.07
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.52M	$29.43M
YoY Change	-20.08%	194.01%
Cash & Equivalents	$23.52M	$29.43M
Short-Term Investments
Other Short-Term Assets	$1.000M	$400.0K
YoY Change	150.0%	-32.2%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$24.51M	$29.84M
YoY Change	-17.86%	181.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.00K	$70.00K
YoY Change	-14.29%	-12.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$800.0K	$30.00K
YoY Change	2566.67%	200.0%
Total Long-Term Assets	$870.0K	$100.0K
YoY Change	770.0%	11.11%
TOTAL ASSETS
Total Short-Term Assets	$24.51M	$29.84M
Total Long-Term Assets	$870.0K	$100.0K
Total Assets	$25.38M	$29.94M
YoY Change	-15.23%	180.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$260.0K	$550.0K
YoY Change	-52.73%	-55.28%
Accrued Expenses	$980.0K	$510.0K
YoY Change	92.16%	-39.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.240M	$1.070M
YoY Change	15.89%	-48.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$710.0K	$3.690M
YoY Change	-80.76%	-34.11%
Total Long-Term Liabilities	$710.0K	$3.690M
YoY Change	-80.76%	-34.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.240M	$1.070M
Total Long-Term Liabilities	$710.0K	$3.690M
Total Liabilities	$1.940M	$4.760M
YoY Change	-59.24%	-37.94%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.43M	$25.18M
YoY Change
Total Liabilities & Shareholders Equity	$25.38M	$29.94M
YoY Change	-15.23%	180.07%

Cashflow Statement

Concept	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$1.889M	-$3.793M
YoY Change	-50.2%	494.93%
Depreciation, Depletion And Amortization	$12.93K	$14.00K
YoY Change	-7.63%	22.33%
Cash From Operating Activities	-$2.510M	-$1.930M
YoY Change	30.05%	-16.09%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$10.00K
YoY Change	200.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$30.00K	-$10.00K
YoY Change	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	400.0K	5.920M
YoY Change	-93.24%	510.31%
NET CHANGE
Cash From Operating Activities	-2.510M	-1.930M
Cash From Investing Activities	-30.00K	-10.00K
Cash From Financing Activities	400.0K	5.920M
Net Change In Cash	-2.140M	3.980M
YoY Change	-153.77%	-399.25%
FREE CASH FLOW
Cash From Operating Activities	-$2.510M	-$1.930M
Capital Expenditures	-$30.00K	-$10.00K
Free Cash Flow	-$2.480M	-$1.920M
YoY Change	29.17%	-16.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Type DocumentType	10-Q
	imuc	Charge To Financing Expense ChargeToFinancingExpense	34078
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60678764
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55307906
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	ImmunoCellular Therapeutics, Ltd.
	dei	Trading Symbol TradingSymbol	IMUC
CY2014Q3	imuc	Charge To Financing Expense ChargeToFinancingExpense	9478
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	573092
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-603389
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	437423
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7827982
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28975
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-28575
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1045000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53289854
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1045000
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	483455
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	55000
	imuc	Percentage Of Annual Increase Of Monthly Base Rent PercentageOfAnnualIncreaseOfMonthlyBaseRent	0.03
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	100905
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	68432
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	194252
CY2013Q2	imuc	Listing Of Shares Of Common Stock In Connection With Sales Agreement ListingOfSharesOfCommonStockInConnectionWithSalesAgreement	10593220
	imuc	Percentage Of Fair Market Value Of Common Stock PercentageOfFairMarketValueOfCommonStock	not be less than 100%
	imuc	Percentage Of Common Stock Voting Rights Held PercentageOfCommonStockVotingRightsHeld	more than 10%
	imuc	Minimum Percentage Of Fair Market Value Of Common Stock MinimumPercentageOfFairMarketValueOfCommonStock	less than 110%
	imuc	Maximum Exercisable Period Of Options MaximumExercisablePeriodOfOptions	P10Y
	imuc	Maximum Exercisable Period Of Options If Percentage Of Common Stock Voting Rights Held Is More Than Ten Percent MaximumExercisablePeriodOfOptionsIfPercentageOfCommonStockVotingRightsHeldIsMoreThanTenPercent	P5Y
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	12000000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	8000000
CY2005Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6000000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5680731
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10466695
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	547117
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1075000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9469765
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7948459
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.37
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.28
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.08
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.75
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.18
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y5M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y8M23D
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	36400
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	36400
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3300000
	imuc	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Not Yet Recognized Period For Recognition Maximum EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognitionMaximum	19
CY2010Q2	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2011Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2012Q4	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	2823670
	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	2854196
CY2012Q4	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.87
CY2014Q2	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.85
	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	0.89
CY2014Q3	imuc	Change In Fair Value Of Warrant Liability Credited To Other Income ChangeInFairValueOfWarrantLiabilityCreditedToOtherIncome	320167
CY2014Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58933905
	us-gaap	Depreciation Depreciation	36846
	us-gaap	Depreciation Depreciation	35682
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	3
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3817
	us-gaap	Share Based Compensation ShareBasedCompensation	483455
	us-gaap	Share Based Compensation ShareBasedCompensation	500351
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-370438
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-178108
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	147330
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6054663
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37877
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	400
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-37877
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	141631
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4261723
	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	2681448
	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	4906078
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3726448
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9309432
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4130109
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3216892
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26216668
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29433560
	us-gaap	Interest Paid InterestPaid	0
	us-gaap	Interest Paid InterestPaid	0
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
	imuc	Warrant Liability Converted To Additional Paid In Capital Upon Exercise WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise	1145659
	imuc	Common Stock Issued For License Rights CommonStockIssuedForLicenseRights	75000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates<font style="font-style:normal;"> – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.</font></p></div>
	imuc	Change In Fair Value Of Warrant Liability Credited To Other Income ChangeInFairValueOfWarrantLiabilityCreditedToOtherIncome	268527
CY2014Q3	imuc	Working Capital WorkingCapital	23276968
CY2013Q4	imuc	Working Capital WorkingCapital	27007377
	imuc	Maturity Period Of Highly Liquid Instruments To Be Considered As Cash Equivalents Maximum MaturityPeriodOfHighlyLiquidInstrumentsToBeConsideredAsCashEquivalentsMaximum	P90D
CY2014Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	21424604
CY2013Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	25913893
	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	generally three to five years
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0218
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0161
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y5M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M13D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.953
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.906
	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0.00
	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0.00
CY2014Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	56571680
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2014Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19495807
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14610187
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	202260
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	185375
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	144086
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	118933
CY2014Q3	us-gaap	Depreciation Depreciation	12930
CY2013Q3	us-gaap	Depreciation Depreciation	13998
CY2011Q3	imuc	Amount Of Funding From Equity Minimum After Amendment AmountOfFundingFromEquityMinimumAfterAmendment	5000000
CY2010Q4	imuc	Amount Of Funding From Equity Minimum After Amendment AmountOfFundingFromEquityMinimumAfterAmendment	2500000
CY2012Q1	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.87
CY2012Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2823670
CY2013Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	18000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	74000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	24915
CY2006Q4	imuc	Stock Issued During Period Shares Issued For Upfront Licensing Fee StockIssuedDuringPeriodSharesIssuedForUpfrontLicensingFee	694000
CY2013Q2	imuc	Rate Of Commission RateOfCommission	0.030
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	469047
CY2014Q3	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.84
CY2014Q3	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2869696
CY2012Q1	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	1.41
CY2006Q4	imuc	Payment For Upfront Licensing Fee PaymentForUpfrontLicensingFee	62000
CY2008Q4	imuc	Funding From Equity For Milestone Minimum FundingFromEquityForMilestoneMinimum	5000000
	imuc	Payment To Related Party For Clinical Trial PaymentToRelatedPartyForClinicalTrial	166660
CY2008Q2	imuc	Stock Issued During Period Shares Issued For Additional Licensing Fee StockIssuedDuringPeriodSharesIssuedForAdditionalLicensingFee	100000
CY2012Q1	imuc	Common Stock Shares Issuable Private Placement Warrants CommonStockSharesIssuablePrivatePlacementWarrants	4744718
CY2012Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2013	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	0.93
CY2010Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	834455
CY2013Q3	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	210856
CY2010Q3	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	446142
	imuc	Extended Term Of Agreement ExtendedTermOfAgreement	2014-03-31
	imuc	Nonrefundable And Noncreditable License And Maintenance Fee NonrefundableAndNoncreditableLicenseAndMaintenanceFee	P12M
CY2014Q3	us-gaap	Rental Properties RentalProperties	8063
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	25000
CY2012Q1	imuc	Charge To Financing Expense ChargeToFinancingExpense	368524
CY2012Q4	imuc	Charge To Financing Expense ChargeToFinancingExpense	368524
CY2014Q2	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2854196
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2852880
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	34078
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0
	imuc	Warrants Exercised WarrantsExercised	0
	imuc	Warrants Exercised WarrantsExercised	1145659
	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	392940
	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	-1983388
	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0
	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3690609
CY2013Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	-0.02
	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.09
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.42
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.31
	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.00
	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.00
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18693862
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15759274
CY2014Q3	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2214369
CY2013Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2020987
CY2014Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20908231
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17780261
CY2014Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
	imuc	Net Operating Losses Expire Date NetOperatingLossesExpireDate	expire in 2022 and 2016

Files In Submission

Name	View Source	Status
0001564590-14-005433-index-headers.html	Edgar Link	pending
0001564590-14-005433-index.html	Edgar Link	pending
0001564590-14-005433.txt	Edgar Link	pending
0001564590-14-005433-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
imuc-10q_20140930.htm	Edgar Link	pending
imuc-20140930.xml	Edgar Link	completed
imuc-20140930.xsd	Edgar Link	pending
imuc-20140930_cal.xml	Edgar Link	unprocessable
imuc-20140930_def.xml	Edgar Link	unprocessable
imuc-20140930_lab.xml	Edgar Link	unprocessable
imuc-20140930_pre.xml	Edgar Link	unprocessable
imuc-ex311_201409309.htm	Edgar Link	pending
imuc-ex312_201409308.htm	Edgar Link	pending
imuc-ex321_201409306.htm	Edgar Link	pending
imuc-ex322_201409307.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

2014 Q3 Form 10-Q Financial Statement

#000156459014005433 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC EOM Pharmaceutical Holdings, Inc. Stock $imuc

2014 Q3 Form 10-Q Financial Statement

#000156459014005433 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc